Current treatment status-Not currently treated - Page 5 of 28 Posts on Medivizor
Navigation Menu

Current treatment status-Not currently treated Posts on Medivizor

How effective is involved field radiotherapy after autologous hematopoietic stem-cell transplantation in patients with high-risk relapsed/refractory lymphoma?

How effective is involved field radiotherapy after autologous hematopoietic stem-cell transplantation in patients with high-risk relapsed/refractory lymphoma?

Posted by on Apr 4, 2021 in Non-Hodgkin lymphoma | 0 comments

In a nutshell The authors assessed the safety and efficacy of involved-field radiotherapy (IFRT) after autologous hematopoietic stem-cell transplantation (ASCT) in patients with high-risk relapsed/refractory (r/r) lymphoma. The study found that IFRT given soon after ASCT provided durable responses and was well tolerated in these patients. Some...

Read More

Searching for patients with extensive-stage small cell lung cancer to trial a combination treatment.

Searching for patients with extensive-stage small cell lung cancer to trial a combination treatment.

Posted by on Mar 13, 2021 in Lung cancer | 0 comments

In a nutshell This trial is looking to trial a treatment combination of olaparib (Lynparza), durvalumab (Imfinzi), radiation therapy (RT), and chemotherapy (CT) to treat patients with extensive-stage (ES) small-cell lung cancer (SCLC). The main outcomes to be measured are side effects and survival. This trial is being carried out in Texas,...

Read More

Long-term outcomes of idelalisib treatment for patients with relapsed painless lymphoma

Long-term outcomes of idelalisib treatment for patients with relapsed painless lymphoma

Posted by on Jan 31, 2021 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study reported the long-term effectiveness and safety outcomes of treatment with idelalisib (Zydelig) after a longer follow-up of patients with indolent (painless) non-Hodgkin lymphoma. The data showed that idelalisib treatment improved the overall survival of these patients in the long-term. Some background Non-Hodgkin...

Read More

Looking for patients with HER-2 positive advanced breast cancer to trial an experimental treatment.

Looking for patients with HER-2 positive advanced breast cancer to trial an experimental treatment.

Posted by on Jan 28, 2021 in Breast cancer | 0 comments

In a nutshell This trial is aiming to examine the safety and effectiveness of an experimental treatment called BPX-063, a CAR-T cell treatment, in patients with advanced HER-2 positive breast cancer. The main outcomes to be measured are the maximum tolerated dose of BPX-603 and the antitumor activity. This trial is being carried out across the...

Read More

Looking for patients with relapsed or refractory multiple myeloma to trial a treatment combination

Looking for patients with relapsed or refractory multiple myeloma to trial a treatment combination

Posted by on Jan 28, 2021 in Multiple Myeloma | 0 comments

In a nutshell This trial is aiming to examine the effectiveness of combination therapy with venetoclax (Venclexta), daratumumab (Darzalex), and dexamethasone (Ozurdex) with or without bortezomib (Velcade) for unresponsive or relapsed multiple myeloma (MM). The main outcome that is to be measured is the response rate, time to response,...

Read More

Comparing the GDP and ICE regimens as salvage treatment for relapsed/refractory aggressive lymphoma

Comparing the GDP and ICE regimens as salvage treatment for relapsed/refractory aggressive lymphoma

Posted by on Jan 17, 2021 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study investigated the effectiveness and safety of GDP (gemcitabine, dexamethasone, and cisplatin) and ICE (ifosfamide, carboplatin, and etoposide) regimens as salvage therapy in patients with relapsed/refractory aggressive lymphoma. The data showed that both the GDP and ICE regimens are suitable options for relapsed/refractory...

Read More

Comparing the GDP and ICE regimens as salvage treatment for relapsed/refractory aggressive lymphoma

Comparing the GDP and ICE regimens as salvage treatment for relapsed/refractory aggressive lymphoma

Posted by on Jan 17, 2021 in Hodgkin's lymphoma | 0 comments

In a nutshell This study investigated the effectiveness and safety of GDP (gemcitabine, dexamethasone, and cisplatin) and ICE (ifosfamide, carboplatin, and etoposide) regimens as salvage therapy in patients with relapsed/refractory aggressive lymphoma. The data showed that both the GDP and ICE regimens are suitable options for relapsed/refractory...

Read More

What schedule of panobinostat with subcutaneous bortezomib and dexamethasone tablets is effective for patients with relapsed and refractory multiple myeloma?

What schedule of panobinostat with subcutaneous bortezomib and dexamethasone tablets is effective for patients with relapsed and refractory multiple myeloma?

Posted by on Dec 31, 2020 in Multiple Myeloma | 0 comments

In a nutshell This study evaluated the treatment schedule for panobinostat (Farydak) tablets combines with subcutaneous (injections under the skin) bortezomib (Velcade) and dexamethasone (Ozurdex) tablets in patients with relapsed/refractory (R/R) multiple myeloma (MM). The study found that 20mg of panobinostat should be given twice...

Read More

The effects of tandem autologous-reduced intensity allogeneic stem cell transplantation in patients with high-risk relapsed Hodgkin lymphoma

The effects of tandem autologous-reduced intensity allogeneic stem cell transplantation in patients with high-risk relapsed Hodgkin lymphoma

Posted by on Dec 26, 2020 in Hodgkin's lymphoma | 0 comments

In a nutshell The study evaluated outcomes of tandem autologous stem cell transplantation (ASCT) – reduced-intensity conditioning (RIC) allogeneic stem cell transplantation (alloSCT) in patients with high-risk (HR) relapsed Hodgkin lymphoma (HL). The main finding was that this approach was safe and effective in such patients. Some...

Read More

Comparing the outcomes of utidelone plus capecitabine versus capecitabine alone in patients with previously treated resistant metastatic breast cancer

Comparing the outcomes of utidelone plus capecitabine versus capecitabine alone in patients with previously treated resistant metastatic breast cancer

Posted by on Dec 26, 2020 in Breast cancer | 0 comments

In a nutshell The study compared outcomes of utidelone plus capecitabine (Xeloda) versus capecitabine (C) alone in previously treated patients with anthracycline- and taxane-resistant metastatic breast cancer (MBC). The authors found that this combination improved survival compared to C alone in such patients. Some background...

Read More

Searching for participants with advanced non-small cell lung cancer to trial an experimental therapy

Searching for participants with advanced non-small cell lung cancer to trial an experimental therapy

Posted by on Dec 15, 2020 in Lung cancer | 0 comments

In a nutshell This trial is evaluating the safety and effectiveness of experimental treatment REGN5093 in patients with advanced non-small-cell lung cancer (NSCLC). The main outcomes to be evaluated will be the number of patients who experience side effects, the maximum dose without significant side effects, and response to treatment. This trial is...

Read More

Searching for patients with advanced breast cancer to trial an experimental combination treatment.

Searching for patients with advanced breast cancer to trial an experimental combination treatment.

Posted by on Dec 13, 2020 in Breast cancer | 0 comments

In a nutshell This trial is looking to examine the safety and effectiveness of a new drug called CYH33 in combination with olaparib (Lynparza) for the treatment of advanced solid tumors including breast cancer. The main outcomes that are to be measured are side effects and the response rate to the treatment. This trial is being carried out in...

Read More
ABOUT USHOW IT WORKSBLOG NEWS PARTNERS CONTACT US PRIVACY POLICY TERMS OF USE
FROM OUR BLOG
LATEST NEWS
CONNECT WITH US
© 2024 Medivizor